Evidence map›Paper›PMID 35022697›Full record

SynthesisClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies.

Auke de Zwart, Annelies Riezebos-Brilman, Gerton Lunter, Judith Vonk, Allan R Glanville, Jens Gottlieb, Nitipong Permpalung, Huib Kerstjens, Jan-Willem Alffenaar, Erik Verschuuren

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Anellovirus-mediated interferon dysregulation enhances virus-induced lung injury.American journal of respiratory cell and molecular biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Tolerogenic lung allograft microenvironment suppresses pathogenic tissue remodeling following respiratory virus infection in mice.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. RSV: an overview of infection in adults.Pneumonia (Nathan Qld.) · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 5 countries.

Auke de ZwartUniversity of Groningen, University Medical Center Groningen, Department of Pulmonary Medicine and Tuberculosis, Groningen, The Netherlands.
Annelies Riezebos-BrilmanLaboratory for Medical Microbiology and Public Health, Hengelo, The Netherlands.
Gerton LunterUniversity of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands.
Judith VonkUniversity of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands.
Allan R GlanvilleLung Transplant Unit, St Vincent's Hospital, Sydney, NSW, Australia.
Jens GottliebDepartment of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
Nitipong PermpalungDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Huib KerstjensUniversity of Groningen, University Medical Center Groningen, Department of Pulmonary Medicine and Tuberculosis, Groningen, The Netherlands.
Jan-Willem AlffenaarSchool of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Erik VerschuurenUniversity of Groningen, University Medical Center Groningen, Department of Pulmonary Medicine and Tuberculosis, Groningen, The Netherlands.
University of Groningen · NLJohns Hopkins Medicine · USMedizinische Hochschule Hannover · DESt Vincent's Hospital Sydney · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRespiratory syncytial virus (RSV), parainfluenza virus (PIV), and human metapneumovirus (hMPV) are increasingly associated with chronic lung allograft dysfunction (CLAD) in lung transplant recipients (LTR). This systematic review primarily aimed to assess outcomes of RSV/PIV/hMPV infections in LTR and secondarily to assess evidence regarding the efficacy of ribavirin.

methodsRelevant databases were queried and study outcomes extracted using a standardized method and summarized.

resultsNineteen retrospective and 12 prospective studies were included (total 1060 cases). Pooled 30-day mortality was low (0-3%), but CLAD progression 180-360 days postinfection was substantial (pooled incidences 19-24%) and probably associated with severe infection. Ribavirin trended toward effectiveness for CLAD prevention in exploratory meta-analysis (odds ratio [OR] 0.61, [0.27-1.18]), although results were highly variable between studies.

conclusionsRSV/PIV/hMPV infection was followed by a high CLAD incidence. Treatment options, including ribavirin, are limited. There is an urgent need for high-quality studies to provide better treatment options for these infections.

Indexed as

MetapneumovirusParamyxoviridae InfectionsRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsHumansLungParainfluenza Virus 1, HumanParainfluenza Virus 2, HumanProspective StudiesRetrospective StudiesRibavirinTransplant RecipientsRibavirinlung transplantationparamyxoviruspneumovirusribavirin

Identifiers

PMID35022697
PMCPMC9258934
OpenAlexW4205336047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.